Oral Janus kinase inhibitors (JAKi) have been expanding the treatment landscape for inflammatory rheumatoid diseases for several years. In the following interview, Prof. Dr. med. Gerd Burmester explains what this means for the management of these diseases and what points there are to consider with regard to the effectiveness and safety of JAKi.
This content is machine-translated. Please contact us if you need professional translation services.